and xanthine dehydrogenase.
Mitomycin C (MMC) is an antitumor antibiotic effective against solid tumors, including colorectal tumors. MMC requires bioreductive activation in tumor cells to show its antitumor activity. The bioreductive activation of MMC can occur via two pathways. The first is one-electron reduction, mediated by NADPH:cytochrome P450 reductase, 1, 2) xanthine oxidase, 2) cytochrome b 5 reductase 3) and xanthine dehydrogenase. 4) The second is two-electron reduction. A major two-electron reductase is NAD(P)H: quinone oxidoreductase, which is known as DT-diaphorase (DTD), encoded by the NQO1 gene. 5) DTD plays a major role in the activation of MMC in carcinoma cells because (i) MMC-resistant cell lines show no or only marginal DTD activity [6] [7] [8] [9] [10] [11] [12] [13] [14] ; (ii) introduction of the NQO1 gene into St-4 cells, which express no DTD, renders the cells several times more sensitive to MMC 15) ; and (iii) the amount of DNA-bound MMC is increased in the NQO1 transfectants over the parental St-4 cells. 15) Therefore, clinical measurement of DTD in carcinoma samples could be beneficial in designing adjuvant chemotherapy involving MMC. DTD activity is usually examined spectroscopically by measuring dicoumarol-sensitive reduction of 2,6-dichlorophenol indophenol (DCPIP). 16) This procedure is complicated and time-consuming. In clinical tumor samples, enzyme activity is relatively unstable and can be affected by contaminants such as antioxidants and related enzymes. Therefore, an alternative method is needed to quantitate DTD effectively in large numbers of clinical tumor samples.
We previously developed an anti-human DTD monoclonal antibody. 14) Using this antibody in immunoblot analyses, we measured DTD protein expression and compared it with DTD enzyme activity. We found that the protein expression was closely correlated with the enzyme activity in the carcinoma cell lines and in the colorectal tumor samples. We also found that colorectal tumors with metastasis showed higher DTD levels than did tumors without metastasis. 14) and five gastric carcinoma cell lines (St-4, MKN7, MKN28, MKN45 and MKN74) were used in this study. All cell lines were cultured in RPMI 1640 medium (Nissui, Tokyo) containing 10% fetal bovine serum (Life Technologies, Inc., Grand Island, NY) and 100 µg/ml of kanamycin (Meiji Seika, Tokyo) and were maintained in a humidified atmosphere of 95% air-5% CO 2 at 37°C. Growth inhibition by MMC The growth inhibition assay was performed as previously described. 17) In brief, exponentially growing cells were plated into 6-well plates in 2 ml of growth medium. The colon cell lines were plated at a density of 2×10 4 cells/ml, and the gastric cell lines were plated at a density of 4×10 4 cells/ml. After an overnight culture at 37°C, graded concentrations of MMC were added to the medium. After 2 days, cells were trypsinized and counted with a Coulter Counter. The drug concentrations that inhibit cell growth by 50% (IC 50 values) were determined as described previously.
MATERIALS AND METHODS

Chemicals
18)
Preparation of cell lysates The cultured cell lines were grown to subconfluence under standard conditions. The cell layer was washed with phosphate-buffered saline (136.9 mM NaCl, 2.7 mM KCl, 8.1 mM Na 2 HPO 4 and 1.5 mM KH 2 PO 4 ) and harvested. The pelleted cells were then suspended in ice-cold reticulocyte standard buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl and 1.5 mM MgCl 2 ) containing 0.1 mM phenylmethylsulfonyl fluoride, lysed by sonication for 10 s and centrifuged at 1,500g for 10 min at 4°C to obtain the supernatant lysate. When clinically excised samples were used, the tumors and surrounding normal tissues were immediately trimmed to 0.5 cm 3 fragments after tumor resection. The samples were homogenized using a Dounce-type homogenizer (30 strokes) in ice-cold reticulocyte standard buffer and centrifuged at 1,500g for 10 min at 4°C. Enzyme activity analysis The lysates were further centrifuged at 105,000g for 30 min at 4°C to obtain clear cytosol as the enzyme source. Protein concentrations were determined with a bicinchoninic acid protein assay kit (Pierce Chemical Co., Rockford, IL). DTD activity was assayed according to the method of Ernster, 16) as modified by Benson et al. 19) Immunoblot analysis Whole lysates were subjected to immunoblot analysis without further fractionation. The immunoblot analysis of DTD was performed using a mouse anti-human DTD monoclonal antibody developed in our laboratory.
14) The DTD protein bands were detected by enhanced chemiluminescence with the western blotting protocol (Amersham Japan, Tokyo), and the density of each protein band was measured using an Ultra Scan XL (Pharmacia, Uppsala, Sweden). 
RESULTS
Correlation between DTD protein expression and enzyme activities in cell lines
The amount of DTD protein was examined by immunoblot analysis in eight colon and five gastric carcinoma cell lines (Fig. 1) . Most of the cell lines showed a 32-kDa protein band, depending on their expression levels. Among the colon cell lines, HCC2998 showed the highest level of DTD protein band, while HCT116 showed only a faint band. HT-29/MMC cells, which are resistant to MMC due to deficient DTD activity, exhibited no DTD protein band, as reported previously. 14) In gastric cell lines, MKN45 cells expressed the highest level of DTD. MKN7 cells and St-4 cells did not express DTD.
The DTD expression levels were normalized by taking HT-29 cells as the 100% control value. We also measured the DTD enzyme activity in the cell lines and compared the DTD protein levels with the enzyme activity. There was a good correlation (r=0.939) between expression and activity (Fig. 2) . We previously reported that cell lines with zero or marginal DTD activity showed resistance to MMC. 15) In accordance with this, cell lines with no DTD protein expression were resistant to MMC (Fig. 1) . Expression of DTD in surgically excised tumor samples To examine the correlation between DTD protein expression and enzyme activity in clinical tumor samples, we measured DTD expression and activity in 20 surgically excised samples from colorectal tumors. In ten out of 20 cases, normal peripheral tissues were isolated from surgically resected tumor samples and compared with the tumors for expression of DTD (Fig. 3) . We could detect the 32-kDa DTD protein band in the samples, as we had in the carcinoma cell lines. In five cases, tumors expressed higher levels of DTD than did the associated normal tissues (patients 1, 5, 6, 9, 10), as reported previously. [20] [21] [22] [23] This indicates selective toxicity of MMC to tumors.
We then compared DTD activity in the 20 tumor samples, including the 10 samples mentioned above, with their DTD protein levels. Again, the level of DTD protein expression correlated closely with DTD activity (r=0.938) (Fig. 4) . This indicates that DTD activity in clinical tumor samples could be measured quantitatively by examining DTD protein expression on immunoblots. Table I summarizes the clinicopathological features and DTD expression of the tumors tested. There were 13 male and 7 female patients; the mean age was 67.2 years, ranging from 51 to 78 years. Histologically, all tumors were adenocarcinomas. Interestingly, when the tumors were classified according to the presence or absence of nodal metastasis, tumors with metastases (Dukes C tumors) expressed larger amounts of DTD protein than did tumors without metastases (Dukes A and B tumors). The difference in DTD enzyme activity between these tumors was statistically significant (P<0.05, by Mann-Whitney U- 
DISCUSSION
Since DTD activity is required for cytotoxicity of MMC in vitro, as we reported previously, 14, 15) measuring DTD in surgical tumor samples could be beneficial for predicting the sensitivity of remaining or metastasized tumors to adjuvant chemotherapy with MMC. Clinically speaking, a practical and consistent method of measuring DTD activity in tumor specimens from patients is needed.
In this study, we demonstrated that immunological quantitation of DTD protein is an alternative and easy method for measuring DTD.
In comparing this method with the classical enzymatic method, we found the following advantages in the immunological approach: (i) many tumors can be examined at one time without concern for enzyme inactivation; (ii) preparation of tumor lysates for immunological detection is simplified because ultracentrifugation is not required; and (iii) detection of DTD protein is not affected by antioxidants, which influence DTD enzyme activity. Immunoblotting, however, can give only a relative level of DTD expression, while enzymatic examination provides absolute activity. The sensitivity of immunoblotting is also inferior, in that in our study the DTD protein band was barely detectable in tumor samples with DTD activity below 100 nmol/min/mg protein ( Fig. 3 and Table I ). However, the DTD expression can be normalized by comparing it with expression in a standard cell line, as we did in HT-29. It is important to discriminate between tumors with minimal DTD expression and DTD-expressing tumors, since carcinoma cells with little or no DTD are resistant to MMC (Fig. 1) . Immunoblot analysis can distinguish such tumors. Taking these observations into consideration, we believe that the immunological method is useful to quantitate DTD expression for large numbers of clinical cases.
When tumors were classified according to the presence or absence of nodal metastasis, those with metastases (Dukes C) expressed higher levels of DTD than did nonmetastatic tumors (Dukes A and B). Since the enzymatic method is more sensitive than immunoblot analysis, we performed statistical comparison with DTD enzyme activity. We found that tumors with nodal metastases showed significantly higher DTD activity than did nonmetastatic tumors (P<0.05, by Mann-Whitney U-test; Table I ). Thus, it is likely that the increased expression of DTD is associated with malignancy in colorectal tumors, although the role of DTD in the malignant progression remains to be determined.
The therapeutic implications of such DTD measurements suggest that chemotherapy involving MMC may be ineffective for patients with tumors that do not express DTD because they can not activate MMC. Conversely, patients with advanced colorectal tumors that express DTD could have a positive response to MMC treatment. However, it has not been demonstrated in clinical tumors that DTD deficiency correlates with poor treatment outcome in chemotherapy involving MMC. We expect advanced colorectal carcinoma with nodal metastasis to be sensitive to MMC, but we did not test for sensitivity to MMC in clinically resected tumors. Further studies are required to elucidate the clinical significance of DTD in carcinomas.
